title: Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion.
abstract: OBJECTIVE
  Peritoneal mesothelioma (PM) is a rare disease, with a poor prognosis. We decided to prospectively evaluate the prognostic impact of aggressive surgery followed by intraperitoneal chemotherapy with local hyperthermia.
  
  
  METHODS
  In this prospective study, 19 patients with PM were treated by cytoreductive surgery (CRS) and intraperitoneal hyperthermic perfusion (IPHP). Mean follow-up was 27 months (range: 1-65). Fifteen (68%) patients had malignant disease, two had well-differentiated papillary mesothelioma, and two had multicystic PM. Thirteen (65%) patients received preoperative chemotherapy. Fifteen cases (75%) underwent optimal cytoreduction (residual disease <2.5 mm). One patient underwent the procedure twice due to locoregional progression. IPHP was performed with closed abdomen technique, using a preheated polysaline perfusate (42.5 degrees C) containing cisplatin + mitomycin C or cisplatin + doxorubicin administered through a heart-lung pump for 60 or 90 min.
  
  
  RESULTS
  Three-year overall and progression-free survival was 69 and 66%, respectively. The operative morbidity (grade II/III), mortality, and overall toxicity (grade I-IV) rates were 25, 0, and 30%, respectively. Seventeen (94%) out of 18 patients had resolution of ascites.
  
  
  CONCLUSIONS
  This therapeutic strategy proved feasible and was well tolerated. Early results seem promising and consistent with a potentially major impact on survival in selected patients with PM.
authors.affiliation: Department of Surgery, National Cancer Institute of Milan, Milan, Italy. marcello.deraco@istitutotumori.mi.it
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
authors.forename: Paolo
authors.initials: P
authors.lastname: Casali
authors.forename: M G
authors.initials: MG
authors.lastname: Inglese
authors.forename: Dario
authors.initials: D
authors.lastname: Baratti
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Pennacchioli
authors.forename: Rossella
authors.initials: R
authors.lastname: Bertulli
authors.forename: Shigeki
authors.initials: S
authors.lastname: Kusamura
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D004333:Drug Administration Routes; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D007263:Infusions, Parenteral; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000601:surgery* / Q000628:therapy; D011446:Prospective Studies; D016019:Survival Analysis
chemical_list: D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin